Biotech ETF XBI rallies with 58% gain in a year, bullish outlook for 2026 on rate cuts, M&A, and AI drug discovery.

The State Street SPDR S&P Biotech ETF (XBI) has surged 58% over the past year, recovering from a post-pandemic drop of over 50%. Analysts from Goldman Sachs and Mizuho are bullish on biotech for 2026, citing expected interest rate cuts that will lower financing costs, increased mergers and acquisitions driven by big pharma seeking new drug pipelines, and accelerated drug discovery through AI technology. XBI's equal-weighted structure favors smaller biotech firms poised for breakthroughs, and it avoids heavy exposure to Covid-19 vaccine makers, which face ongoing risk concerns. With nearly 45 points of upside potential before hitting its all-time high, biotech investors see strong growth opportunities ahead.